Merck KGaA will start construction next month on a plant to make diabetes drugs in China, a market it says is key to its future. The market is so important that the executive board of the German drugmaker held an event there to reiterate that point to Chinese officials.
Personalized medicine is the latest trend in companion diagnostics, and companies are teaming up to develop comprehensive tests based on a patient's biologic characteristics. Roche's Ventana Medical Systems sees potential in the field, and recently inked a deal with Germany's Merck KGaA to develop a companion diagnostic test for different cancer indications.
Having already bought the land on which Merck KGaA's salt plant in Lehrte, Germany, sits, salt maker Schüssler Novachem has now bought the production and laboratory equipment from the German drugmaker.
The FDA gave de novo approval to Menlo Park-based Auxogyn's Eeva System, a fertility-enhancing diagnostic test currently available in Europe and Canada.
The market for multiple sclerosis drugs is not an easy one, especially now that Biogen Idec's soaring Tecfidera has arrived on the scene. But MS drugmakers Novartis and Merck KGaA are doing what they can to keep their edges, rolling out a pair of digital solutions to help patients manage the disease.
Merck KGaA has been investing steadily in its manufacturing operations the last couple of years, and now a fill-finish plant in Italy is slated to get a €50 million infusion as Merck forges ahead in preparation for selling more biologic drugs.
Merck KGaA has breathed some life back into its lung cancer vaccine, which many wrote off after it tanked in a Phase III trial in late 2012. After vowing to make a renewed effort to find some value in the jab last September, this week the company announced the start of a new Phase III study.
Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.
Last month Pfizer and the Broad Institute published details of their work to find diabetes drug targets in genome data. Now Pfizer has teamed with Merck KGaA to give the institute another pot of cash to investigate lupus.
Merck KGaA last year closed manufacturing facilities as part of a major restructuring to cut costs. This year it is planning to build them to serve areas that it has decided have the greatest potential as well as expected growth in emerging markets.